Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

BridgeBio Pharma (BBIO) has disclosed Restructuring Costs for 4 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Restructuring Costs rose 137.18% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 58.98% year-over-year, with the annual reading at $21.3 million for FY2025, 36.8% up from the prior year.
  • Restructuring Costs hit $11.1 million in Q4 2025 for BridgeBio Pharma, up from $8.8 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $22.7 million in Q1 2022 to a low of $272000.0 in Q3 2023.
  • Historically, Restructuring Costs has averaged $5.4 million across 4 years, with a median of $4.1 million in 2023.
  • Biggest five-year swings in Restructuring Costs: plummeted 94.58% in 2023 and later soared 1598.9% in 2024.
  • Year by year, Restructuring Costs stood at $7.7 million in 2022, then crashed by 90.2% to $754000.0 in 2023, then soared by 522.41% to $4.7 million in 2024, then skyrocketed by 137.18% to $11.1 million in 2025.
  • Business Quant data shows Restructuring Costs for BBIO at $11.1 million in Q4 2025, $8.8 million in Q3 2025, and $712000.0 in Q2 2025.